PL2626368T3 - Koniugaty insulina-oligomer, ich formulacje i zastosowania - Google Patents

Koniugaty insulina-oligomer, ich formulacje i zastosowania

Info

Publication number
PL2626368T3
PL2626368T3 PL13166899T PL13166899T PL2626368T3 PL 2626368 T3 PL2626368 T3 PL 2626368T3 PL 13166899 T PL13166899 T PL 13166899T PL 13166899 T PL13166899 T PL 13166899T PL 2626368 T3 PL2626368 T3 PL 2626368T3
Authority
PL
Poland
Prior art keywords
insulin
formulations
oligomer conjugates
conjugates
oligomer
Prior art date
Application number
PL13166899T
Other languages
English (en)
Inventor
Balasingam Radhakrishnan
Diti Aggarwal
Michelle Ferro
Kenneth D. James
Navdeep B. Malkar
Mark A. Miller
Leo Pavliv
Karen Polowy
Karen Puskas
Nnochiril N. Ekwuribe
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Publication of PL2626368T3 publication Critical patent/PL2626368T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13166899T 2004-07-19 2005-07-19 Koniugaty insulina-oligomer, ich formulacje i zastosowania PL2626368T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58905804P 2004-07-19 2004-07-19
US61915304P 2004-10-15 2004-10-15
US63257804P 2004-12-02 2004-12-02
US65583805P 2005-02-24 2005-02-24
US65580305P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
PL2626368T3 true PL2626368T3 (pl) 2017-06-30

Family

ID=35787693

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05773736T PL1773878T3 (pl) 2004-07-19 2005-07-19 Koniugaty insulina-oligomer, ich formulacje i zastosowania
PL13166899T PL2626368T3 (pl) 2004-07-19 2005-07-19 Koniugaty insulina-oligomer, ich formulacje i zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL05773736T PL1773878T3 (pl) 2004-07-19 2005-07-19 Koniugaty insulina-oligomer, ich formulacje i zastosowania

Country Status (20)

Country Link
US (6) US7605123B2 (pl)
EP (2) EP2626368B1 (pl)
JP (3) JP5220410B2 (pl)
KR (2) KR101309770B1 (pl)
CN (3) CN103223160B (pl)
AU (1) AU2005269753B2 (pl)
BR (1) BRPI0513508B1 (pl)
CA (2) CA2580313C (pl)
DK (2) DK2626368T3 (pl)
ES (2) ES2535823T3 (pl)
IL (3) IL180762A (pl)
MX (1) MX2007000883A (pl)
NO (2) NO345613B1 (pl)
NZ (1) NZ553263A (pl)
PL (2) PL1773878T3 (pl)
PT (2) PT1773878E (pl)
RU (2) RU2527893C2 (pl)
UA (2) UA91512C2 (pl)
WO (1) WO2006014673A2 (pl)
ZA (1) ZA200701446B (pl)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
DE60335608D1 (de) * 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
DK1648933T3 (da) * 2003-07-25 2009-09-07 Conjuchem Biotechnologies Inc Langvarige insulinderivater og fremgangsm der
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2007029238A2 (en) * 2005-09-06 2007-03-15 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
CN101573133B (zh) * 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
RU2524150C2 (ru) * 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
JP5496082B2 (ja) * 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
CN101677944A (zh) * 2007-06-01 2010-03-24 诺沃-诺迪斯克有限公司 稳定的非含水药物组合物
EP2017288A1 (en) * 2007-07-16 2009-01-21 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
RU2453332C2 (ru) * 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
BRPI0820535B8 (pt) 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
MX2010005317A (es) * 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
WO2009070234A2 (en) 2007-11-21 2009-06-04 The University Of The Sciences In Philadelphia Complexation of fatty acid-conjugated molecules with albumin
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009112583A2 (en) * 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
NZ588603A (en) * 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
JP2011519373A (ja) 2008-05-01 2011-07-07 コンプレクザ インコーポレイテッド ビニル置換脂肪酸
US20110046053A1 (en) 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
RU2517135C2 (ru) * 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Композиции пептидов и способы их получения
CN102088991A (zh) 2008-05-13 2011-06-08 堪萨斯大学 金属提取肽标签和相关方法
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2299997A4 (en) 2008-06-19 2012-01-11 Univ Utah Res Found USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
PL2300514T3 (pl) * 2008-07-14 2016-09-30 Sposób syntezowania zasadniczo monodyspersyjnej mieszaniny oligomerów
EP2334335A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of cd-np peptides
WO2010088268A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010088300A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Crystalline insulin-conjugates
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
CA2751854A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
US9095623B2 (en) * 2009-03-20 2015-08-04 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US8623345B2 (en) * 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
WO2010120365A2 (en) * 2009-04-16 2010-10-21 Wu Nian Protein-carrier conjugates
US20120241356A1 (en) * 2009-07-06 2012-09-27 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
EP3045167A1 (en) 2009-07-31 2016-07-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Keto fatty acids as anti-inflammatory agents
EP2483233A4 (en) 2009-10-02 2013-08-14 Complexa Inc HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
JP2013507414A (ja) 2009-10-13 2013-03-04 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト
ES2552401T3 (es) * 2009-11-02 2015-11-27 Novo Nordisk A/S Solución farmacéutica de albúmina unida no covalentemente e insulina acilada
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US20110319325A1 (en) * 2010-06-28 2011-12-29 Complexa, Inc. Multi-component pharmaceuticals for treating diabetes
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
EP2598522A4 (en) 2010-07-28 2014-11-12 Smartcells Inc RECOMBINANT LKTINE, BINDING POINT MODIFIED LECTIN AND APPLICATIONS THEREOF
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
CN102614498B (zh) * 2011-01-28 2014-12-17 四川科伦药物研究有限公司 一种胰岛素纳米粒及其制备方法
CN102675452B (zh) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
US9944688B2 (en) * 2011-06-02 2018-04-17 Hanmi Science Co., Ltd. Non-peptidyl polymer-insulin multimer and method for producing the same
CN103596584B (zh) 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
EP3260131A1 (en) 2012-01-03 2017-12-27 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
CN113769074A (zh) 2012-02-01 2021-12-10 奥拉姆德有限公司 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US9096679B2 (en) * 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
JP6377070B2 (ja) 2012-12-03 2018-08-22 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ ペプチド化合物及びその製造方法及びその使用
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
WO2014106846A2 (en) 2013-01-03 2014-07-10 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
CA2908693C (en) 2013-04-16 2021-04-06 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
US20200157159A1 (en) 2013-04-16 2020-05-21 The Board Of Regents Of The University Of Oklahoma Peptide compounds and compositions thereof
KR20160065930A (ko) 2013-10-04 2016-06-09 머크 샤프 앤드 돔 코포레이션 글루코스-반응성 인슐린 접합체
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
US9822158B2 (en) 2013-12-04 2017-11-21 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP6574556B2 (ja) * 2014-08-27 2019-09-11 日東電工株式会社 口腔内フィルム状基剤及び製剤
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
CN104447981B (zh) * 2014-12-25 2015-07-08 重庆浦诺维生物科技有限公司 端羟基聚乙二醇化的人胰岛素及其类似物的偶联物
WO2016119854A1 (en) * 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
PT3865484T (pt) 2015-07-07 2024-01-30 H Lundbeck As Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017059451A1 (en) 2015-10-02 2017-04-06 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
MX376641B (es) 2015-11-13 2025-03-07 Univ Massachusetts Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia.
EP3384935A4 (en) * 2015-12-02 2019-08-21 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX WITH FATTY ACID DERIVATIVE AND MANUFACTURING METHOD THEREFOR
WO2017175522A1 (ja) * 2016-04-05 2017-10-12 株式会社Moresco オキサ酸化合物
US10458409B2 (en) * 2016-06-06 2019-10-29 Emerson Climate Technologies, Inc. Compressor having a sleeve guide assembly
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
KR102396217B1 (ko) * 2017-09-19 2022-05-09 임문워크 아이엔씨 알부민과의 결합 친화성이 증대된 약학 구조물
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
JP2021528424A (ja) * 2018-06-18 2021-10-21 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 対象における食後のグルコースレベルをコントロールする方法および使用
CA3110680A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
WO2020144606A1 (en) * 2019-01-10 2020-07-16 Biocon Limited Preparative crystallization of recombinant human insulin
CN114887039B (zh) * 2022-05-13 2026-01-30 西北工业大学 一种锌离子介导的自组装胰岛素纳米药物、制备方法和应用
WO2024079739A1 (en) * 2022-10-14 2024-04-18 Bhami's Research Laboratory, Pvt. Ltd. Polypeptide formulations for oral delivery

Family Cites Families (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2789080A (en) * 1952-08-14 1957-04-16 Christensen Henry Marinus Insulin-albumin compositions
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3058885A (en) 1957-06-08 1962-10-16 Novo Terapeutisk Labor As Process for treatment of insulin crystals and for production of insulin preparationstherefrom
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3014842A (en) 1957-08-10 1961-12-26 Novo Terapeutish Lab A S Injectable bovine insulin crystal suspensions and process of producing same
US3091573A (en) * 1958-05-12 1963-05-28 Novo Terapeutisk Labor As Quick acting insulin preparation
US3256153A (en) * 1963-02-08 1966-06-14 Smith Kline French Lab Method of stabilizing wax-fat coating materials and product thereof
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4093574A (en) * 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4087390A (en) 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4087930A (en) * 1976-10-20 1978-05-09 O. F. Mossberg & Sons, Inc. Magazine cap retaining means for tubular magazine firearms
US4223163A (en) * 1976-12-10 1980-09-16 The Procter & Gamble Company Process for making ethoxylated fatty alcohols with narrow polyethoxy chain distribution
JPS53116315A (en) 1977-03-17 1978-10-11 Ueno Seiyaku Oyo Kenkyujo Kk Powder or granular containing improved sorbinic acid
US4100117A (en) * 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4253998A (en) 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) * 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
US4348387A (en) * 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
US4469681A (en) 1979-07-31 1984-09-04 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
JPS5692846A (en) 1979-12-27 1981-07-27 Takeda Chem Ind Ltd Tetrapeptide derivative and its preparation
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1144743B (it) * 1981-07-09 1986-10-29 Mario Cane Apparecchio infusore di insulina perfezionato
US4654324A (en) * 1981-08-27 1987-03-31 Eli Lilly And Company Human proinsulin pharmaceutical formulations
US4476113A (en) 1981-10-27 1984-10-09 Union Oil Company Of California Stabilized fumigant composition comprising an aqueous solution of ammonia, hydrogen sulfide, carbon disulfide and sulfur
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4698264A (en) * 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4602043A (en) * 1983-07-18 1986-07-22 Technology Unlimited Inc. Treatment for hypoglycemia
JPS6032714A (ja) * 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
JPS60130003A (ja) 1983-12-16 1985-07-11 日本特殊陶業株式会社 高周波用誘電体磁器組成物
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4704394A (en) * 1984-04-25 1987-11-03 Technology Unlimited, Inc. Treatment for hyperactivity
US4849405A (en) * 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4761287A (en) * 1984-05-03 1988-08-02 Technology Unlimited, Inc. Diabetes control by serotonin
US4863896A (en) * 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4797288A (en) 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
US4946828A (en) 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
US5157021A (en) * 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
ZA877505B (en) 1986-10-14 1989-05-30 Lilly Co Eli Process for transforming a human insulin precursor to human insulin
GB8706313D0 (en) 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
US5093198A (en) * 1987-06-19 1992-03-03 Temple University Adjuvant-enhanced sustained release composition and method for making
US4822337A (en) * 1987-06-22 1989-04-18 Stanley Newhouse Insulin delivery method and apparatus
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5034415A (en) * 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
JPH01308231A (ja) 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
US5055300A (en) 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5306500A (en) 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5468727A (en) 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
FR2675807B1 (fr) 1991-04-23 1994-07-01 Medgenix Group Sa Conjugue de calcitonine et de polyethylene glycol.
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
CA2114141A1 (en) 1991-07-26 1993-02-18 Panayiotis Pericleous Constantinides W/o microemulsions
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5693769A (en) 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
DK0621777T3 (da) 1992-01-17 1996-10-21 Alfatec Pharma Gmbh Pellets indeholdende aktivt stof og med en matrix af hydrofile makromolekyler, og fremgangsmåde til deres fremstilling
US5876754A (en) * 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
GB9212511D0 (en) 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5420108A (en) 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US6093391A (en) 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5364838A (en) * 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
GB9406094D0 (en) 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
WO1995030641A1 (en) 1994-05-10 1995-11-16 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
DE69533987T2 (de) 1994-05-20 2006-03-16 Hisamitsu Pharmaceutical Co., Inc., Tosu Protein oder polypeptid, verfahren zur seiner herstellung und entsprechende zwischenprodukte
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
PE32296A1 (es) * 1994-07-28 1996-08-07 Hoffmann La Roche Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5543414A (en) 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
NZ293163A (en) 1994-09-21 1998-09-24 Inhale Therapeutic Syst Inhalation medicament disperser, aerosol from high pressure gas entrainment of fluidised powder drawn from receptacle feed tube
CN1080575C (zh) * 1994-10-14 2002-03-13 蛋白质传送股份有限公司 结合稳定的多肽组合物、其治疗、诊断制剂及其制备和使用方法
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
FI972443A7 (fi) 1994-12-07 1997-06-09 Novozymes As Polypeptidi, jonka allergeenisuus on vähentynyt
GB9424902D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5606038A (en) 1995-04-10 1997-02-25 Competitive Technologies, Inc. Amphiphilic polyene macrolide antibiotic compounds
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
ES2093593T1 (es) 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US20010041786A1 (en) 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
EP0835129B1 (en) 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
WO1997014740A1 (en) 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
FR2746035B1 (fr) 1996-03-15 1998-06-12 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
US6103270A (en) 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
US5856369A (en) 1996-07-30 1999-01-05 Osi Specialties, Inc. Polyethers and polysiloxane copolymers manufactured with double metal cyanide catalysts
DE19632440A1 (de) 1996-08-12 1998-02-19 Basf Ag Verfahren zur Herstellung von aus Polykationen aufgebauten, geformten Mischhydroxiden
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US6011008A (en) 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
US5830918A (en) 1997-01-15 1998-11-03 Terrapin Technologies, Inc. Nonpeptide insulin receptor agonists
PT1017408E (pt) 1997-02-05 2005-07-29 Hoffmann La Roche Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US6043214A (en) 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
KR19980075132A (ko) * 1997-03-28 1998-11-05 민병무 중간사슬지방산(medium-chain fatty acids)을 유효성분으로 하는 치아우식증 및 치주질환 치료제용 의약조성물
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
JPH1112177A (ja) 1997-06-25 1999-01-19 Teikoku Seiyaku Co Ltd 安定なアスピリン含有外用製剤
US6068993A (en) 1997-07-02 2000-05-30 Biobras Sa Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin
US20020115609A1 (en) 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
GEP20022707B (en) 1997-07-18 2002-06-25 Infimed Inc Us Biodegrading Macromers for the Controlled Release of Biologically Active Substances
US6182712B1 (en) 1997-07-21 2001-02-06 Inhale Therapeutic Systems Power filling apparatus and methods for their use
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
RU2117488C1 (ru) * 1997-07-30 1998-08-20 Институт нефтехимического синтеза им.А.В.Топчиева РАН Твердое инсулинсодержащее лекарственное средство
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
RU2218349C2 (ru) * 1997-10-24 2003-12-10 Ново Нордиск А/С Агрегаты производных инсулина человека
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
KR100253916B1 (ko) 1997-12-29 2000-05-01 김충환 사람 인슐린 전구체의 제조방법
WO1999034821A1 (en) 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6192887B1 (en) * 1998-05-19 2001-02-27 The Pennsylvania State University Broad spectrum microbicidal and spermicidal compositions and methods having activity against sexually transmitted agents including papillomaviruses
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US5968554A (en) 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation
US20030049654A1 (en) 1998-10-16 2003-03-13 Xencor Protein design automation for protein libraries
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
EP1131089B1 (en) 1998-11-18 2004-02-18 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
WO2000043034A2 (en) * 1999-01-26 2000-07-27 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
EP1223986A2 (en) 1999-06-11 2002-07-24 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol)
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
DK1808438T3 (da) 1999-06-29 2014-10-27 Mannkind Corp Rensning og stabilisering af peptid og proteiner i lægemidler
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
NZ518401A (en) 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
CN1312080A (zh) * 2000-02-18 2001-09-12 日本脏器制药株式会社 含有脂肪酸的组合物
AU2001266392A1 (en) 2000-06-27 2002-01-08 Mi Tech Company Limited The controlled release preparation of insulin and its method
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
CN1507357A (zh) * 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
CN100439397C (zh) 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
CZ20033182A3 (cs) * 2001-05-21 2004-09-15 Nektar Therapeutics Inzulínový prostředek a způsob podávání inzulínu
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20030040601A1 (en) 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
UY27439A1 (es) 2001-09-07 2003-04-30 Nobex Corp Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
CN1170851C (zh) * 2001-09-27 2004-10-13 华中科技大学 治疗糖尿病的口服药脂肪二酰氨基酸胰岛素及其合成方法
WO2003049701A2 (en) 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
WO2003051304A2 (en) 2001-12-15 2003-06-26 Spherics, Inc. Bioadhesive drug delivery system with enhanced gastric retention
KR20040066177A (ko) * 2001-12-19 2004-07-23 알자 코포레이션 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태
WO2004060347A2 (en) 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
AU2002255196A1 (en) 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
EP1536835A1 (en) 2002-07-09 2005-06-08 Sandoz AG Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
DE10250297A1 (de) 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
US20040235948A1 (en) * 2003-03-05 2004-11-25 Solvay Pharmaceuticals Gmbh Treatment of diabetic patients with omega-3-fatty acids
MXPA05009933A (es) * 2003-03-18 2005-11-04 Novartis Ag Composiciones que comprenden acidos grasos y aminoacidos.
AU2004264958B2 (en) 2003-08-13 2010-04-15 Biocon, Ltd Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
US7192919B2 (en) * 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
DE602004014716D1 (de) * 2004-03-06 2008-08-14 Cognis Ip Man Gmbh Use of unsaturated fatty acids for the reduction of appetite or food intake

Also Published As

Publication number Publication date
PT2626368T (pt) 2017-03-10
AU2005269753A2 (en) 2006-02-09
EP1773878B1 (en) 2015-03-04
CA2910494C (en) 2018-10-23
UA103758C2 (ru) 2013-11-25
PT1773878E (pt) 2015-06-05
ES2535823T3 (es) 2015-05-18
AU2005269753A1 (en) 2006-02-09
JP5721266B2 (ja) 2015-05-20
EP2626368A3 (en) 2013-10-16
JP5220410B2 (ja) 2013-06-26
JP2011236233A (ja) 2011-11-24
US20110124553A1 (en) 2011-05-26
WO2006014673A2 (en) 2006-02-09
US20060019874A1 (en) 2006-01-26
NO20170341A1 (no) 2007-01-22
AU2005269753B2 (en) 2011-08-18
US20060019873A1 (en) 2006-01-26
EP1773878A4 (en) 2012-06-20
RU2393168C2 (ru) 2010-06-27
US20060018874A1 (en) 2006-01-26
CA2580313A1 (en) 2006-02-09
CA2910494A1 (en) 2006-02-09
DK2626368T3 (en) 2017-02-27
KR20070059060A (ko) 2007-06-11
US9102758B2 (en) 2015-08-11
ES2618028T3 (es) 2017-06-20
US8563685B2 (en) 2013-10-22
JP2014043470A (ja) 2014-03-13
RU2010105921A (ru) 2011-08-27
US7872095B2 (en) 2011-01-18
KR101309770B1 (ko) 2013-09-30
JP2008506782A (ja) 2008-03-06
BRPI0513508B1 (pt) 2021-06-01
JP5750494B2 (ja) 2015-07-22
IL180762A (en) 2015-06-30
NO340825B1 (no) 2017-06-26
CN101027318B (zh) 2016-05-25
NO20070859L (no) 2007-04-12
CN103223160B (zh) 2015-02-18
US9101596B2 (en) 2015-08-11
PL1773878T3 (pl) 2015-07-31
KR101276754B1 (ko) 2013-06-19
BRPI0513508A (pt) 2008-05-06
CA2580313C (en) 2016-03-15
CN105801686B (zh) 2020-04-07
UA91512C2 (ru) 2010-08-10
US7875700B2 (en) 2011-01-25
EP2626368A2 (en) 2013-08-14
ZA200701446B (en) 2008-09-25
IL209494A0 (en) 2011-01-31
DK1773878T3 (en) 2015-05-11
WO2006014673A3 (en) 2006-08-17
IL227117A (en) 2017-02-28
US20100105605A1 (en) 2010-04-29
IL209494A (en) 2015-07-30
EP1773878A2 (en) 2007-04-18
CN101027318A (zh) 2007-08-29
RU2007105824A (ru) 2008-08-27
IL180762A0 (en) 2007-06-03
EP2626368B1 (en) 2016-12-21
US7605123B2 (en) 2009-10-20
MX2007000883A (es) 2007-04-02
RU2527893C2 (ru) 2014-09-10
HK1187826A1 (en) 2014-04-17
NO345613B1 (no) 2021-05-10
CN103223160A (zh) 2013-07-31
CN105801686A (zh) 2016-07-27
NZ553263A (en) 2010-06-25
US20110118179A1 (en) 2011-05-19
KR20120120985A (ko) 2012-11-02

Similar Documents

Publication Publication Date Title
IL180762A0 (en) Insulin-oligomer conjugates, formulations and uses thereof
IL179633A0 (en) Drug compositions, fusions and conjugates
IL179521A0 (en) Natriuretic compounds, conjugates, and uses thereof
IL189245A0 (en) Interleukin-1 conjugates and uses thereof
IL186521A0 (en) Nanoparticle-active ingredient conjugates
GB0414825D0 (en) Gel formulations and uses thereof
PL1877073T3 (pl) Niecytotoksyczne koniugaty białkowe
IL183582A0 (en) Polymer conjugates and methods for the preparation thereof
IL187479A0 (en) Antigen conjugates and uses thereof
IL176918A0 (en) Ghrelin-carrier conjugates
PL1814977T3 (pl) Kompozycje na bazie arthrospira i ich zastosowania
IL181300A0 (en) Photosensitizer formulations and uses thereof
IL179497A0 (en) Carboranylporphyrins and uses thereof
IL180365A0 (en) Carboranylporphyrins and uses thereof
IL181228A0 (en) Vlp-antigen conjugates and their uses as vaccines
GB0406048D0 (en) Drug formulations
IL177759A0 (en) Cospeptin, cosmedin and their uses
AU2011205115B2 (en) Insulin-oligomer conjugates, formulations and uses thereof
IL179208A0 (en) Intereferon formulations
ZA200701667B (en) VLP-antigen conjugates and their use as vaccines
GB0417226D0 (en) Formulations
GB0417248D0 (en) Formulations
EP1841406A4 (en) METHOD AND FORMULATIONS
GB0420820D0 (en) Novel formulations
GB0426293D0 (en) Novel formulations